entecavir + IDS

The name **entecavir + IDS** appears to be a transcription error or misidentification of **ETV:IDS** (also known as **DNL310**), an investigational enzyme replacement therapy developed by **Denali Therapeutics** for the treatment of **Hunter Syndrome (Mucopolysaccharidosis Type II)**. The error likely stems from mistaking the 'ETV' abbreviation—which stands for Denali's proprietary **Enzyme Transport Vehicle** platform—for the Hepatitis B antiviral drug entecavir. ETV:IDS is a recombinant fusion protein consisting of the enzyme **iduronate 2-sulfatase (IDS)** fused to a transport vehicle designed to cross the blood-brain barrier via receptor-mediated transcytosis, addressing both the systemic and central nervous system manifestations of MPS II. The provided context incorrectly attributes this program to **Pluvia Biotech**, a company whose actual lead program targets phenylalanine hydroxylase (PAH) for the treatment of PKU; the source materials referenced in the context are confirmed to be from Denali Therapeutics' pipeline.